India, Aug. 27 -- Shares of Abivax SA (ABVX) are trading at an all-time high of $80, thanks to the recently announced encouraging clinical trial results for its experimental ulcerative colitis drug, Obefazimod.
Obefazimod is being evaluated in a pivotal global phase III clinical trial program in moderately to severely active ulcerative colitis, dubbed ABTECT.
The ABTECT program consists of two 8-week induction trials, dubbed ABTECT-1 and ABTECT-2, and a 44-week maintenance trial. In the trials, the efficacy and safety of 50mg and 25mg doses of Obefazimod, administered once daily (QD), are compared to those of the placebo.
The company reported positive topline results from its Phase 3 ABTECT-1 and ABTECT-2 induction trials on July 22, 202...